GLP-1 RAS has reduced cardiovascular risk in metabolic hepatic diseases

Topline:

The use of Peptide 1 receptor agonists similar to glucagon (GLP-1) in patients with metabolic dysfunction-associated hepatic disease (old) has been associated with a low risk for new onset, compound cardiovascular events, clinically significant portal hypertension events and mortality.

METHODOLOGY:

• GLP-1 RAS is a promising treatment for patients with type 2 diabetes and have cardiovascular benefits, but their effect data in olive patients are rare.
• The researchers carried out a retrospect cohort study using the Trinetx database to examine the grated GLP-1 effects in adult patients with MAlD or Metabolic Associated Steatohepatitis (Mash).
• Patients were divided into groups depending on the fact that they received GLP-1 RAS (treatment group) or did not receive GLP-1 laugh after diagnosis (control group).
• The primary results were the incidence or new onset of major adverse cardiovascular events, classified as heart failure and composite cardiovascular events, as well as clinically significant portal hypertension events; The secondary result was mortality for all causes.
• The tracking assessments were carried out at 1, 3, 5 and 7 years.

TAKE AWAY:

• The researchers identified 634,265 patients, of which 23,551 received GLP-1 RAS and 610.714 NO.
• After applying the propensity score to take into account the confusing variables, 6243 patients were included in the treatment group (average age, 55.3 years; 63% women) and the control group (average age, 55.5 years; 64.5% women).
• At 7 years old, the GLP-1 RA group had a significantly lower risk for heart failure (hazard report (HR), 0.72; P <.01), composite cardiovascular events (HR, 0.59; P <.0001), clinically significant portal hypertension events (HR, 0.46; P <.0001) and mortality for all causes (HR, 0.30; P <.0001) than the control group.
• These beneficial effects remained consistent on all points of time evaluated at 1, 3, 5 and 7 years since the index events.

IN PRACTICE:

“These results emphasize the potential clinical value of the GLP-1 agonists in Masld and Mash Management,” the authors wrote.

SOURCE:

This study was conducted by Brandon Havranek, Sidney Kimmel Medical College from Thomas Jefferson University, Philadelphia and published online in Scientific reports.

Limitations:

The study was based on electronic medical records for the diagnosis of patients with masld without imaging or histological confirmation, increasing the possibility of the wrong diagnosis. The high proportion of patients with diabetes in Masld cohorts has made it difficult to distinguish the specific cardiovascular benefits from those specific to diabetes. The study did not evaluate the result differences between different GLP-1 RAS, which could have provided an additional perspective on their relative effectiveness.

Disclosures:

This study was supported by the open access fund of Thomas Jefferson University. An author has revealed the position of consultant and received research funding from various pharmaceutical companies.

This article was created using several editorial tools, including you, as part of the process. Human publishers examined this content before publishing.